Glaucoma Clinical Trials

Find Glaucoma Clinical Trials Near You

Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Glaucoma is the most common threat to vision rehabilitation in patients with Boston keratoprosthesis type 1 (KPro) implantation. High intraocular pressure (IOP) is the most important risk factor for glaucoma and may lead to irreversible retinal and optic nerve damage. Glaucoma drainage device (GDD) surgery is used to divert aqueous humor (AH) from the anterior chamber to an external reservoir to regulate flow and decrease the IOP. The AH is in direct communication with any corneal damage or surgery undertaken in the anterior chamber and can serve as a source of potential biomarkers to detect early inflammatory or glaucomatous changes. Tears are also one of the most accessible and non-invasive source of biomarkers, especially in Kpro eyes where the central optic allows communication between aqueous humor and the tears at the surface of the eye. The investigators propose to test the hypothesis that distinct inflammatory mediators in the AH and tears can serve as biomarkers for glaucoma development and progression after CT, making them specifically amenable to targeted treatment strategies to minimize vision loss.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Aged 18 years old or older

• Informed consent

• Ability to be followed for the duration of the study

• Presence of ocular disease specified for each group

⁃ Specific criteria for each group:

• Group 1 : have no glaucoma and no systemic diseases

• Group 2 : need to have glaucoma filtration surgery without prior corneal transplantation

• Group 3 : need to have corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma

• Group 4 : need to have intraocular surgery after prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)

• Group 5 : need to have glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)

Locations
Other Locations
Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
RECRUITING
Montreal
Contact Information
Primary
Marie-Catherine Tessier, M.Sc.
marie-catherine.tessier.chum@ssss.gouv.qc.ca
1-514-890-8000
Backup
Dominique Geoffrion, B.Sc.
dominique.geoffrion@mail.mcgill.ca
1-514-890-8000
Time Frame
Start Date: 2020-05-11
Estimated Completion Date: 2029-05
Participants
Target number of participants: 200
Treatments
Sham_comparator: Cataract surgery only
Participants needing cataract surgery, without glaucoma or any other corneal diseases.
Sham_comparator: Glaucoma surgery only
Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
Experimental: Corneal transplantation
Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure.
Experimental: Intraocular surgery following corneal transplantation
Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation.
Experimental: Glaucoma surgery following corneal transplantation
Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation.
Sponsors
Leads: Centre hospitalier de l'Université de Montréal (CHUM)

This content was sourced from clinicaltrials.gov